You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

How does the 30-day cost of Relvar for the treatment of asthma compare to other ICS/LABA combination inhalers?

Please click on the thumbnail to the left to view and download a pdf copy of a cost comparison chart of ICS/LABAs available for the treatment of asthma. Relvar Ellipta low-mid dose (92/22mcg) and high dose (184/22mcg) are highlighted in orange.

The cost comparison chart is updated regularly to reflect the change in list price of ICS/LABAs inhalers.

If you would like to estimate the potential financial impact of adopting Relvar Ellipta for the treatment of asthma in your health economy please contact a Health Outcomes Consultant (HOC). The HOC will model and localise the estimate using prescribing data for your own health economy.

To arrange a meeting with a HOC use the following link:

Please state your preference to either meet in person, telephone or on-line.

Please note: Dose categories are as per the BTS/SIGN asthma guideline.[1]

Prescribing decisions should not be based on cost alone. You should refer to the SPC of each medicine for further information such as indications, contraindications, precautions and adverse events.[2]


  1. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma 2016. Available at:
  2. Summary of Product Characteristics. Available at:  

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Relvar, Ellipta, Seretide, Accuhaler and Evohaler are registered trademarks of the GlaxoSmithKline group of companies